Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹2,420.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹312.39B
Enterprise Value₹210.41K
Total Cash (Recent Filing)₹6.62B
Total Debt (Recent Filing)₹22.33B
Price to Earnings (P/E)146.7
Beta1.20
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.11
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Return To ProfitabilitySustained top‑line growth (+~12% in FY2026) and a return to positive net income indicate the company has stabilized core operations and resumed earnings generation. Over 2–6 months this supports reinvestment, credibility with creditors and partners, and a higher likelihood of consistent operating performance if trends persist.
Improved Balance-sheet CushioningA stronger equity base and broadly stable leverage provide enhanced financial flexibility to absorb shocks or fund strategic investments. Over months this reduces refinancing risk and supports capacity for capex or working capital needs, improving long‑term resilience versus earlier weaker capital positions.
Diversified Pharma Business ModelMultiple revenue streams (branded formulations, API supply, contract manufacturing) and geographic reach create durable earnings sources and cross‑subsidy opportunities. Structural diversification helps absorb product‑level shocks, supports margin mix improvement, and enhances growth optionality over the medium term.
Bears Say
Inconsistent Historical ProfitabilityPrior consecutive years of losses and large swings in operating profit demonstrate earnings fragility. This pattern raises the risk that current profitability may reverse if market or product conditions deteriorate, complicating planning and reducing the predictability of free cash flow over the coming months.
Uneven Cash Generation And Modest Free Cash FlowVolatile operating cash conversion and a sharp drop in free cash flow highlight weak conversion of profits into durable cash. Limited free cash constrains debt reduction, R&D or capex funding without external financing and increases vulnerability to working capital swings over the medium term.
Regulatory/approval DependencyReliance on regulatory approvals to access higher‑margin regulated markets is an enduring operational risk. Delays or setbacks in approvals can materially affect revenue mix and margins, and require sustained compliance investment, making growth outcomes less certain across a 2–6 month horizon.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹2420.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹312.39B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Aug 07, 2026 which is in 16 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on May 04, 2026. The company reported ₹10.216 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹10.216 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.216%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Alkem Laboratories Ltd.
―
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―